Marshall Wace
XGN icon

Marshall Wace’s Exagen XGN Stock Holding History

Marshall Wace’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
306,703
+279,414
+1,024% +$1.05M ﹤0.01% 2028
2026
Q1 		$81.9K Sell
27,289
-216,135
-89% -$836K ﹤0.01% 2926
2025
Q4 		$1.48M Buy
243,424
+218,792
+888% +$1.99M ﹤0.01% 1734
2025
Q3 		$271K Buy
+24,632
New +$218K ﹤0.01% 2469
2025
Q2 		– Sell
-106,559
Closed -$383K – 3244
2025
Q1 		$383K Buy
106,559
+90,511
+564% +$342K ﹤0.01% 2178
2024
Q4 		$65.8K Buy
+16,048
New +$57.8K ﹤0.01% 2473

Other funds holding XGN

NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Marshall Wace's XGN Position: Q2 2026 in Review

Marshall Wace increased its Exagen (XGN) stake by 1,024% in Q2 2026, buying an estimated $1.05M and bringing the position to 306,703 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

Marshall Wace first reported a position in XGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.48M in Q4 2025. 52 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Marshall Wace held 306,703 shares of Exagen worth $1.43M as of Q2 2026.
  • Marshall Wace bought 279,414 Exagen shares in Q2 2026, an estimated $1.05M.
  • Exagen made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2028 holding.
  • Marshall Wace first reported a position in Exagen in Q4 2024 and has held it in 6 quarters since.
  • Marshall Wace's Exagen position peaked at $1.48M in Q4 2025.
  • 52 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.